Search Clinical Trials in the European Union

6-12 months
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
301-320 of 397 trials

Duchenne Muscular Dystrophy: ENTR-601-45 Treatment Study

We are evaluating a new treatment for Duchenne muscular dystrophy to see if it is safe and well-tolerated. This study will help us understand how the treatment works in the body.

Duchenne Muscular Dystrophy6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Grass Pollen Allergy: CLU-RX-PHL Treatment

We are testing a new subcutaneous treatment for people with grass pollen allergy. The study aims to find the most effective and safest dose to help manage allergy symptoms.

Allergic Rhinitis Due to Pollen6-12 monthsEfficacy phase (II)Confirmation phase (III)Investigational MedicinesAllergologyInternal Medicine

Advanced Non-Small Cell Lung Cancer: M9140 Treatment Study

We are studying a new drug called M9140 for people with advanced non-small cell lung cancer. The goal is to see how well it works and how safe it is compared to existing treatments.

Non-Small Cell Lung Cancer6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Advanced Pancreatic Cancer: M9140 Treatment Study

We are studying a new drug called M9140 for people with advanced pancreatic cancer to see how well it works and how safe it is. This trial aims to evaluate its effectiveness and side effects compared to standard treatments.

Metastatic Pancreatic Cancer6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Graves' Ophthalmopathy: Diclofenac vs. Simvastatin

We are studying whether diclofenac or simvastatin can help patients with mild to moderate Graves' ophthalmopathy. The trial aims to assess the activity of the disease and its progression to more severe forms.

Graves' Ophthalmopathy6-12 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsStandard MedicinesEndocrinologyOphthalmology

Moderate-to-Severe Asthma: PF-07275315 Study

We are investigating a new medication called PF-07275315 for adults with moderate-to-severe asthma. The study aims to see if it is more effective than a placebo in improving asthma control and quality of life.

Moderate-to-Severe Asthma6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementAllergologyPulmonology

ANCA-Associated Vasculitis: Rituximab Treatment Study

We are comparing a combination of rituximab and cyclophosphamide to standard treatment for achieving remission in severe ANCA-associated vasculitis. The trial also looks at how different ways of giving rituximab can help maintain remission.

ANCA-Associated Vasculitis6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineRheumatology

Turner Syndrome: Estrogen Therapy Comparison

We are studying the long-term effects of oral versus transdermal estrogen replacement therapy in women with Turner syndrome. This research aims to clarify health risks and benefits associated with each treatment method.

Turner's Syndrome6-12 monthsMonitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyInternal Medicine

Colorectal Cancer: Telisotuzumab Adizutecan Treatment

We are studying a new treatment for adults with colorectal cancer who have positive circulating tumor DNA but no visible disease. The goal is to see if this treatment improves disease-free survival compared to standard care.

Colorectal Cancer6-12 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology

Skin Irritation Study: New 5% Lidocaine Plaster

We are testing a new medicated plaster to see if it causes skin irritation or sensitization in healthy volunteers. This research aims to ensure the safety of the product for future use.

Post Herpetic Neuralgia6-12 monthsSafety phase (I)DermatologyNeurology

Schizophrenia: Cariprazine for Cognitive Function

We are studying how cariprazine affects cognitive functioning in patients with schizophrenia who need changes to their current treatment. The trial will also look at overall quality of life and any side effects.

Acute Schizophrenia6-12 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPsychiatry

Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder

We are studying whether a high dose of psilocybin can help reduce heavy drinking in people with severe alcohol use disorder during inpatient rehabilitation. This trial also examines the safety and effects on mental health and cognitive function.

Severe Alcohol Use Disorder6-12 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementInfectious DiseasesPsychiatry

Polymyalgia Rheumatica: Hydrocortisone Supplement Study

We are investigating whether supplemental hydrocortisone helps improve quality of life for patients with polymyalgia rheumatica or giant cell arteritis experiencing adrenal insufficiency. The focus is on how it affects fatigue during stress.

Glucocorticoid Induced Adrenal Insufficiency6-12 monthsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyRheumatology

Idiopathic Pulmonary Fibrosis: CAL101 Treatment Study

We are studying whether CAL101 can improve lung function in patients with idiopathic pulmonary fibrosis compared to a placebo. The trial also looks at the safety of this new treatment.

Idiopathic Pulmonary Fibrosis6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Heart Failure: PF-07328948 Study

We are testing a new oral medication for adults with heart failure to see if it improves heart function and symptoms compared to a placebo. The study also examines the safety of this treatment.

Heart Failure6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Drug Interaction Study: Itraconazole and AZD5004

We are investigating how multiple doses of itraconazole affect the movement of AZD5004 in healthy adults. Additionally, we’re looking at how AZD5004 influences the movement of hormones in healthy women.

Healthy Participants6-12 monthsSafety phase (I)Gynecology and ObstetricsInternal Medicine

Type 2 Diabetes: Once-Weekly Retatrutide

We are investigating how well once-weekly Retatrutide works for people with type 2 diabetes and its effects on blood sugar levels. This study aims to understand the risk of hypoglycemia in participants.

Type 2 Diabetes6-12 monthsSafety phase (I)DiabetologyEndocrinology

Healthy Adults: Effect of High-Fat Meal on DO-2

We are studying how a high-fat meal influences the way the medication DO-2 is absorbed in healthy individuals. This research may help us understand the best way to use this treatment.

Healthy Volunteers6-12 monthsSafety phase (I)Internal Medicine

Lung Cancer Treatment: Telisotuzumab Adizutecan with Osimertinib

We are studying a new combination treatment for adults with advanced EGFR-mutated non-small cell lung cancer. The goal is to see if this approach is safer and more effective than current standard treatments.

Non-Small Cell Lung Cancer6-12 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Clostridioides difficile Infection: Shorter Vancomycin Treatment

We are studying whether a 5-day course of oral vancomycin is as effective as the standard 10-day treatment for Clostridioides difficile infection. This trial will also assess recovery rates and safety for participants.

Clostridioides difficile Infection6-12 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesGastroenterologyInfectious Diseases